研究者業績

近藤 征史

Masashi Kondo

基本情報

所属
藤田医科大学 医学部 医学科 臨床教授
学位
MD(名古屋大学)

J-GLOBAL ID
200901094395610085
researchmap会員ID
6000001874

肺癌の胸部悪性腫瘍のトランスレーショナル研究、臨床研究を従事している。

論文

 196
  • 田中 佑典, 石井 友里加, 伊奈 拓摩, 丹羽 義和, 山蔦 久美子, 相馬 智英, 堀口 智也, 後藤 康洋, 磯谷 澄都, 橋本 直純, 近藤 征史, 今泉 和良
    肺癌 63(7) 1021-1021 2023年12月  
  • Takenao Koseki, Mayumi Teramachi, Minako Koga, Minoru S. H. Ko, Tomokazu Amano, Hong Yu, Misa Amano, Erica Leyder, Maria Badiola, Priyanka Ray, Jiyoung Kim, Akihiro C. Ko, Achouak Achour, Nan-ping Weng, Takumi Imai, Hisako Yoshida, Satsuki Taniuchi, Ayumi Shintani, Hidetsugu Fujigaki, Masashi Kondo, Yohei Doi
    Vaccines 11(12) 1767-1767 2023年11月27日  
    mRNA vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have played a key role in reducing morbidity and mortality from coronavirus disease 2019 (COVID-19). We conducted a double-blind, placebo-controlled phase I/II trial to evaluate the safety, tolerability, and immunogenicity of EXG-5003, a two-dose, controllable self-replicating RNA vaccine against SARS-CoV-2. EXG-5003 encodes the receptor binding domain (RBD) of SARS-CoV-2 and was administered intradermally without lipid nanoparticles (LNPs). The participants were followed for 12 months. Forty healthy participants were enrolled in Cohort 1 (5 µg per dose, n = 16; placebo, n = 4) and Cohort 2 (25 µg per dose, n = 16; placebo, n = 4). No safety concerns were observed with EXG-5003 administration. SARS-CoV-2 RBD antibody titers and neutralizing antibody titers were not elevated in either cohort. Elicitation of antigen-specific cellular immunity was observed in the EXG-5003 recipients in Cohort 2. At the 12-month follow-up, participants who had received an approved mRNA vaccine (BNT162b2 or mRNA-1273) >1 month after receiving the second dose of EXG-5003 showed higher cellular responses compared with equivalently vaccinated participants in the placebo group. The findings suggest a priming effect of EXG-5003 on the long-term cellular immunity of approved SARS-CoV-2 mRNA vaccines.
  • Aya Hanamoto, Takenao Koseki, Ayaka Utsunomiya, Takuma Ishihara, Takao Tobe, Masashi Kondo, Yuko Kijima, Hiroshi Matsuoka, Tomohiro Mizuno, Takahiro Hayashi, Shigeki Yamada
    Journal of Clinical Medicine 12(22) 6997-6997 2023年11月9日  
    Naldemedine is structurally designed to prevent passage across the blood–brain barrier (BBB), resulting in the attenuation of opioid-induced constipation without interfering with the analgesic effects of opioids. However, the influence of brain metastasis (BM), as one indicator of BBB disruption, on the analgesic effects of opioids in patients treated with naldemedine remains unclear. To examine whether the analgesic effects of opioids following naldemedine treatment are lower in patients with BM than in those without BM, we surveyed inpatients with lung and breast cancers treated with naldemedine at Fujita Health University Hospital between April 2017 and March 2022. Changes in the numeric rating scale (NRS) scores, morphine milligram equivalents (MMEs), and the number of rescues were assessed as analgesia-related outcomes during the first 7 days of naldemedine treatment in patients with or without BM, matched by the propensity score. In total, 172 patients were enrolled. After propensity-score matching, 30 patients with BM and 60 patients without BM were included in the analysis. Changes in NRS scores, MMEs, and the number of rescues did not differ between patients with and without BM. In the linear mixed-effects model, the coefficient of interaction between patients with or without BM and the days for each outcome was not statistically significant. BM does not influence the analgesic effect of opioids in patients with lung and breast cancers treated with naldemedine. Naldemedine may be useful for treating BM.
  • 池田 安紀, 大矢 由子, 佐藤 孝哉, 丹羽 義和, 堀口 智也, 岡地 祥太郎, 後藤 康洋, 磯谷 澄都, 橋本 直純, 近藤 征史, 今泉 和良
    日本気胸・嚢胞性肺疾患学会雑誌 23(2) 73-73 2023年8月  
  • Takahiro Hatta, Tetsunari Hase, Toru Hara, Tomoki Kimura, Eiji Kojima, Takashi Abe, Yoshitsugu Horio, Yasuhiro Goto, Naoya Ozawa, Naoyuki Yogo, Hirofumi Shibata, Tomoya Shimokata, Tetsuya Oguri, Masashi Yamamoto, Kiyoshi Yanagisawa, Masahiko Ando, Yuichi Ando, Masashi Kondo, Makoto Ishii, Yoshinori Hasegawa
    Cancer medicine 2023年6月23日  
    BACKGROUND: The Cockcroft-Gault formula is commonly used as a substitute for glomerular filtration rate (GFR) in Calvert's formula for carboplatin dosing, where adjusting serum creatinine measured using the enzymatic method with 0.2 mg/dL has been suggested in Japan. However, the effects of these adjustments on efficacy in patients with non-small-cell lung cancer remain unknown. METHODS: We conducted a post hoc analysis of the PREDICT1 study (CJLSG1201), a multicenter prospective observational trial of carboplatin-pemetrexed. Glomerular filtration rate values in Calvert's formula were back-calculated from the administered dosages of carboplatin and the reported value of the target area under the curve. We estimated the serum creatinine adjustments and divided the patients into crude and adjusted groups. RESULTS: Patients in the crude group (N = 169) demonstrated similar efficacy to those in the adjusted group (N = 104) in progression-free survival (PFS) and overall survival (OS) (hazard ratio [HR], 1.02; 95% confidence interval [CI], 0.76-1.35; p = 0.916 vs. HR, 0.87; 95% CI, 0.65-1.17; p = 0.363), with higher grade 3-4 hematologic toxicity. Among patients aged ≥75 years, the crude group (N = 47) showed superior efficacy compared with the adjusted group (N = 17) in PFS and OS (HR, 0.37; 95% CI, 0.20-0.69; p = 0.002 vs. HR, 0.43; 95% CI, 0.23-0.82; p = 0.010). CONCLUSIONS: Serum creatinine adjustment may be associated with similar efficacy compared to the crude serum creatinine value. In older patients, the adjustment should be cautiously applied owing to the potential for reduced efficacy.

MISC

 279
  • 相馬智英, 長谷川新, 堀口智也, 岡村拓哉, 大矢由子, 魚津桜子, 後藤康洋, 磯谷澄都, 橋本直純, 近藤征史, 今泉和良
    日本呼吸器学会誌(Web) 12 2023年  
  • 堀口智也, 伊奈拓摩, 魚津桜子, 後藤康洋, 磯谷澄都, 橋本直純, 近藤征史, 今泉和良
    日本呼吸器学会誌(Web) 12 2023年  
  • 重康善子, 堀口智也, 伊奈拓磨, 後藤康洋, 磯谷澄都, 近藤征史, 今泉和良, 大野城二
    気管支学 44(5) 2022年  
  • Takuya Okamura, Sumito Isogai, Naoki Yamamoto, Yoshikazu Niwa, Takayuki Inoue, Maeda Shingo, Takuma Ina, Maeda Yuri, Yasuhiro Goto, Masashi Kondo, Kazuyoshi Imaizumi
    Allergology International 70(3) 401-403 2021年7月  
  • 山本直樹, 山本直樹, 平松範子, 佐々木洋, 近藤征史, 小島肇
    Journal of Toxicological Sciences 46(Supplement) 2021年  
  • 堀口智也, 外山陽子, 丹羽義和, 榊原洋介, 岡村拓哉, 魚津桜子, 後藤康洋, 近藤征史, 今泉和良
    日本呼吸器学会誌(Web) 10 2021年  
  • 魚津桜子, 伊奈拓摩, 井上敬浩, 相馬智英, 渡邊俊和, 堀口智也, 丹羽義和, 榊原洋介, 岡村拓哉, 三重野ゆうき, 後藤康洋, 磯谷澄都, 近藤征史, 今泉和良
    日本呼吸器学会誌(Web) 10 2021年  
  • 井上敬浩, 磯谷澄都, 廣地真理子, 前田侑里, 前田真吾, 相馬智英, 渡邊俊和, 堀口智也, 丹羽義和, 岡村拓哉, 後藤康洋, 近藤征史, 今泉和良
    日本呼吸器学会誌(Web) 10 2021年  
  • 渡邊俊和, 井上敬浩, 前田真吾, 前田侑里, 堀口智也, 丹羽義和, 榊原洋介, 岡村拓哉, 三重野ゆうき, 魚津桜子, 後藤康洋, 磯谷澄都, 近藤征史, 今泉和良
    日本呼吸器学会誌(Web) 10 2021年  
  • 相馬智英, 重康善子, 岡村拓哉, 廣地真理子, 伊奈拓摩, 前田侑里, 榊原洋介, 魚津桜子, 三重野ゆうき, 後藤康洋, 磯谷澄都, 近藤征史, 今泉和良
    日本呼吸器学会誌(Web) 10 2021年  
  • 森谷遼馬, 前田真吾, 榊原洋介, 岡村拓哉, 魚津桜子, 後藤康洋, 近藤征史, 今泉和良, 星川康
    肺癌(Web) 61(1) 2021年  
  • 外山陽子, 堀口智也, 井上敬浩, 丹羽義和, 榊原洋介, 岡村拓哉, 後藤康洋, 磯谷澄都, 近藤征史, 今泉和良
    日本呼吸器学会誌(Web) 10 2021年  
  • 堀口智也, 渡邊俊和, 丹羽義和, 岡村拓哉, 後藤康洋, 磯谷澄都, 近藤征史, 今泉和良
    気管支学 43 2021年  
  • 伊奈拓摩, 岡村拓哉, 榊原洋介, 堀口智也, 後藤康洋, 磯谷澄都, 近藤征史, 今泉和良
    気管支学 43 2021年  
  • Tomohide Souma, Tomoyuki Minezawa, Hiroshi Yatsuya, Takuya Okamura, Kumiko Yamatsuta, Sayako Morikawa, Tomoya Horiguchi, Shingo Maeda, Yasuhiro Goto, Masamichi Hayashi, Sumito Isogai, Naoki Yamamoto, Masashi Kondo, Kazuyoshi Imaizumi
    Chest 158(2) 797-807 2020年3月4日  
    BACKGROUND: Infectious complications after endobronchial ultrasound-guided transbronchial biopsy with a guide sheath (EBUS-GS-TBB) are serious in that they may delay or change scheduled subsequent therapy. The aim of this study was to identify risk factors for infection after EBUS-GS-TBB. RESEARCH QUESTION: ▪▪▪ STUDY DESIGN AND METHODS: We retrospectively reviewed the medical records of 1,045 consecutive patients who had undergone EBUS-GS-TBB for peripheral lung lesions between January 2013 and December 2017 at Fujita Health University Hospital. We evaluated the following risk factors for infectious complications after EBUS-GS-TBB: relevant patient characteristics (age and comorbidities), lesion size, CT scan features of target lesion (intratumoral low-density areas [LDAs] and cavitation), stenosis of responsible bronchus observed by bronchoscopy, and laboratory data before EBUS-GS-TBB (WBC count and C-reactive protein concentration). RESULTS: Forty-seven of the study patients developed infectious complications (24 with pneumonia, 14 with intratumoral infection, three with lung abscess, three with pleuritis, and three with empyema), among whom the complication caused a delay in cancer treatment in 13 patients, cancellation of cancer treatment in seven patients, and death in three patients. Multivariate analysis showed that cavitation (P = .007), intratumoral LDAs (P < .001), and stenosis of responsible bronchus observed by bronchoscopy (P < .001) were significantly associated with infectious complications after EBUS-GS-TBB. Prophylactic antibiotics had been administered to 13 patients in the infection group. Propensity matched analysis could not show significant benefit of prophylactic antibiotics in preventing post-EBUS-GS-TBB infections. INTERPRETATION: Cavitation, LDAs for CT scan features of target lesions, and stenosis of responsible bronchus observed by bronchoscopy are risk factors of post-EBUS-GS-TBB infection. In the cohort, prophylactic antibiotics failed to prevent infectious complications.
  • 相馬智英, 森川紗也子, 加古寿志, 伊奈拓摩, 榊原洋介, 岡村拓哉, 後藤康洋, 林正道, 磯谷澄都, 近藤征史, 今泉和良
    肺癌(Web) 60(2) 2020年  
  • 相馬智英, 峯澤智之, 岡村拓哉, 森川紗也子, 榊原洋介, 魚津桜子, 後藤康洋, 林正道, 磯谷澄都, 近藤征史, 今泉和良
    日本呼吸器学会誌(Web) 9 2020年  
  • 林正道, 三重野ゆうき, 加藤敦, 近藤征史, 今泉和良, 後藤康洋, 魚津桜子, 磯谷澄都, 岡村拓哉, 榊原洋介, 峯澤智之, 森川紗也子
    日本呼吸器学会誌(Web) 9 2020年  
  • 伊奈拓摩, 峯澤智之, 岡村拓哉, 榊原洋介, 森川紗也子, 渡邊俊和, 後藤康洋, 磯谷澄都, 林正道, 近藤征史, 今泉和良
    日本呼吸器学会誌(Web) 9 2020年  
  • 後藤康洋, 廣地真理子, 加古寿志, 池田安紀, 池田安紀, 伊奈拓摩, 前田侑里, 井上敬浩, 前田真吾, 渡邊俊和, 相馬智英, 後藤祐介, 後藤祐介, 堀口智也, 丹羽義和, 森川紗也子, 森川紗也子, 峯澤智之, 榊原洋介, 魚津桜子, 岡村拓哉, 林正道, 林正道, 磯谷澄都, 近藤征史, 今泉和良
    気管支学 42 2020年  
  • 堀口智也, 丹羽義和, 岡村拓哉, 魚津桜子, 後藤康洋, 近藤征史, 今泉和良
    日本肺癌学会総会号 61st 2020年  
  • 今泉和良, 岡村拓哉, 相馬智英, 堀口智也, 丹羽義和, 後藤康洋, 磯谷澄都, 近藤征史, 後藤祐介, 森川紗也子
    気管支学 42 2020年  
  • 渡邊俊和, 伊奈拓摩, 峯澤智之, 相馬智英, 堀口智也, 丹羽義和, 岡村拓哉, 魚津桜子, 後藤康洋, 磯谷澄都, 近藤征史, 今泉和良
    気管支学 42 2020年  
  • 井上敬浩, 磯谷澄都, 堀口智也, 森川紗也子, 丹羽義和, 峯澤智之, 岡村拓哉, 後藤康洋, 林正道, 近藤征史, 今泉和良
    日本呼吸器学会誌(Web) 9 2020年  
  • 渡邊俊和, 伊奈拓摩, 後藤祐介, 堀口智也, 丹羽義和, 森川紗也子, 山蔦久美子, 峯澤智之, 榊原洋介, 岡村拓哉, 三重野ゆうき, 魚津桜子, 後藤康洋, 林正道, 磯谷澄都, 近藤征史, 今泉和良
    日本呼吸器学会誌(Web) 9 2020年  
  • 魚津桜子, 堀口智也, 後藤祐介, 丹羽義和, 森川紗也子, 峯澤智之, 榊原洋介, 岡村拓哉, 三重野ゆうき, 後藤康洋, 林正道, 磯谷澄都, 近藤征史, 今泉和良
    日本呼吸器学会誌(Web) 9 2020年  
  • 後藤康洋, 廣地真理子, 加古寿志, 池田安紀, 伊奈拓摩, 前田侑里, 前田真吾, 井上敬浩, 相馬智英, 渡邊俊和, 堀口智也, 後藤祐介, 丹羽義和, 山蔦久美子, 森川紗也子, 峯澤智之, 榊原洋介, 岡村拓哉, 三重野ゆうき, 魚津桜子, 林正道, 磯谷澄都, 近藤征史, 今泉和良
    日本呼吸器学会誌(Web) 9 2020年  
  • 堀口智也, 後藤康洋, 榊原洋介, 後藤祐介, 丹羽義和, 森川紗也子, 峯澤智之, 岡村拓哉, 三重野ゆうき, 魚津桜子, 林正道, 磯谷澄都, 近藤征史, 今泉和良
    日本呼吸器学会誌(Web) 9 2020年  
  • 榊原 洋介, 磯谷 澄都, 岡村 拓哉, 伊奈 拓摩, 前田 真吾, 井上 敬浩, 相馬 智英, 渡邊 俊和, 堀口 智也, 後藤 祐介, 丹羽 義和, 山蔦 久美子, 森川 紗也子, 魚津 桜子, 三重野 ゆうき, 後藤 康洋, 林 正道, 近藤 征史, 今泉 和良
    藤田学園医学会誌 44(1) 45-50 2020年  
  • Toshikazu Watanabe, Tomoyuki Minezawa, Midori Hasegawa, Yasuhiro Goto, Takuya Okamura, Yosuke Sakakibara, Yoshikazu Niwa, Atsushi Kato, Masamichi Hayashi, Sumito Isogai, Masashi Kondo, Naoki Yamamoto, Naozumi Hashimoto, Kazuyoshi Imaizumi
    BMC pulmonary medicine 19(1) 194-194 2019年11月1日  
    BACKGROUND: Myeloperoxidase anti-neutrophil cytoplasmic antibody-related nephritis (MPO-ANCA nephritis) is occasionally accompanied by lung abnormalities such as pulmonary fibrosis. However, the clinical features of pulmonary fibrosis in patients with MPO-ANCA nephritis have not been well documented. This study was performed to compare the prognosis of a usual interstitial pneumonia (UIP) pattern of lung fibrosis in patients with MPO-ANCA nephritis with the prognosis of idiopathic pulmonary fibrosis (IPF). METHODS: We retrospectively reviewed the medical records of 126 patients with MPO-ANCA nephritis and identified 31 with a UIP pattern of lung fibrosis on high-resolution or thin-slice computed tomography (CT). We compared the characteristics and prognosis of these patients with those of 32 patients with IPF. In 18 patients from both groups, we assessed and compared the decline in lung volume over time using three-dimensional (3D) CT images reconstructed from thin-section CT data. RESULTS: The numbers of male and female patients were nearly equal among patients with MPO-ANCA nephritis exhibiting a UIP pattern; in contrast, significant male dominancy was observed among patients with IPF (p = 0.0021). Significantly fewer smokers were present among the patients with MPO-ANCA nephritis with a UIP pattern than among those with IPF (p = 0.0062). There was no significant difference in the median survival time between patients with MPO-ANCA nephritis with a UIP pattern (50.8 months) and IPF (55.8 months; p = 0.65). All patients with IPF in this cohort received antifibrotic therapy (pirfenidone or nintedanib). Almost half of the deaths that occurred in patients with MPO-ANCA nephritis with a UIP pattern were caused by non-respiratory-related events, whereas most deaths in patients with IPF were caused by respiratory failure such as acute exacerbation. In the 3D CT lung volume analyses, the rate of decline in lung volume was equivalent in both groups. CONCLUSIONS: MPO-ANCA nephritis with a UIP pattern on CT may have an unfavorable prognosis equivalent to that of IPF with a UIP pattern treated with antifibrotic agents.
  • 池田 安紀, 丹羽 義和, 榊原 洋介, 岡村 拓哉, 峯澤 智之, 森川 紗也子, 魚津 桜子, 後藤 康洋, 林 正道, 近藤 征史, 今泉 和良
    肺癌 59(2) 188-188 2019年4月  
  • 相馬智英, 峯澤智之, 岡村拓哉, 榊原洋介, 後藤康洋, 林正道, 磯谷澄都, 近藤征史, 今泉和良
    日本呼吸器学会誌(Web) 8 2019年  
  • 峯澤智之, 岡村拓哉, 榊原洋介, 森川紗也子, 丹羽義和, 井上敬浩, 魚津桜子, 後藤康洋, 林正道, 磯谷澄都, 近藤征史, 今泉和良
    日本呼吸器学会誌(Web) 8 2019年  
  • 加古寿志, 森川紗也子, 榊原洋介, 岡村拓哉, 魚津桜子, 後藤康洋, 林正道, 磯谷澄都, 近藤征史, 今泉和良, 山口哲平
    日本呼吸器学会誌(Web) 8 2019年  
  • 森谷遼馬, 前田真吾, 榊原洋介, 岡村拓哉, 峯澤智之, 森川紗也子, 魚津桜子, 後藤康洋, 林正道, 磯谷澄都, 近藤征史, 今泉和良
    肺癌(Web) 59(7) 2019年  
  • 池田安紀, 丹羽義和, 岡村拓哉, 峯澤智之, 森川紗也子, 魚津桜子, 後藤康弘, 近藤征史, 今泉和良
    気管支学 41 2019年  
  • 池田安紀, 丹羽義和, 榊原洋介, 岡村拓哉, 峯澤智之, 森川紗也子, 魚津桜子, 後藤康洋, 林正道, 近藤征史, 今泉和良
    肺癌(Web) 59(2) 2019年  
  • 磯谷澄都, 平松範子, 山本直樹, 峯澤智之, 榊原洋介, 岡村拓哉, 魚津桜子, 三重野ゆうき, 後藤康洋, 林正道, 近藤征史, 今泉和良
    日本呼吸器学会誌(Web) 8 2019年  
  • 後藤康洋, 今泉和良, 近藤征史, 後藤祐介, 堀口智也, 渡邊俊和, 相馬智英, 井上敬浩, 前田真吾, 加古寿志, 池田安紀
    日本肺癌学会総会号 60th 2019年  
  • 磯谷澄都, 堀口智也, 丹羽義和, 森川紗也子, 峯澤智之, 岡村拓哉, 三重野ゆうき, 後藤康洋, 林正道, 近藤征史, 今泉和良
    アレルギー 68(4/5) 2019年  
  • 後藤康洋, 今泉和良, 近藤征史, 磯谷澄都, 林正道, 魚津桜子, 岡村拓哉, 榊原洋介, 峯澤智之, 山蔦久美子, 丹羽義和, 後藤祐介, 堀口智也, 赤尾謙, 渡邊俊和, 相馬智英, 井上敬浩, 前田真吾, 伊奈拓摩, 前田侑里, 加古寿志, 池田安紀
    日本呼吸器学会誌(Web) 8 2019年  
  • 後藤祐介, 相馬智英, 渡邊俊和, 堀口智也, 丹羽義和, 森川紗也子, 峯澤智之, 榊原洋介, 岡村拓哉, 魚津桜子, 後藤康洋, 林正道, 磯谷澄都, 近藤征史, 今泉和良
    気管支学 41(5) 2019年  
  • 魚津桜子, 後藤祐介, 堀口智也, 丹羽義和, 森川紗也子, 峯澤智之, 榊原洋介, 岡村拓哉, 三重野ゆうき, 後藤康洋, 林正道, 磯谷澄都, 近藤征史, 今泉和良
    日本呼吸器学会誌(Web) 8 2019年  
  • 森川紗也子, 加古寿志, 伊奈拓磨, 前田慎吾, 相馬智英, 渡邊俊和, 赤尾謙, 堀口智也, 後藤祐介, 丹羽義和, 峯澤智之, 岡村拓哉, 魚津桜子, 後藤康洋, 磯谷澄都, 近藤征史, 今泉和良
    気管支学 41 2019年  
  • 後藤祐介, 山口哲平, 峯澤智之, 堀口智也, 岡村拓哉, 後藤康洋, 磯谷澄都, 林正道, 近藤征史, 今泉和良
    日本肺癌学会総会号 60th 2019年  
  • 魚津桜子, 森川沙也子, 渡邊俊和, 相馬智英, 堀口智也, 後藤祐介, 丹羽義和, 峯澤智之, 岡村拓哉, 三重野ゆうき, 後藤康洋, 林正道, 磯谷澄都, 近藤征史, 今泉和良
    日本肺癌学会総会号 60th 2019年  
  • 堀口智也, 森川紗也子, 後藤祐介, 岡村拓哉, 峯澤智之, 魚津桜子, 後藤康洋, 林正道, 近藤征史, 今泉和良
    日本肺癌学会総会号 60th 2019年  
  • Kosuke Takahashi, Masashi Kondo, Masahiko Ando, Akira Shiraki, Harunori Nakashima, Hisashi Wakayama, Kensuke Kataoka, Masashi Yamamoto, Yasuteru Sugino, Mitsunori Nishikawa, Kazuyoshi Imaizumi, Eiji Kojima, Atsushi Sumida, Yoshihiro Takeyama, Hiroshi Saito, Yoshinori Hasegawa
    Oncologist 24(7) e583-e589 2019年1月1日  
    © AlphaMed Press 2019 Background: Although the efficacy of parenteral morphine for alleviating dyspnea has been previously demonstrated in several studies, little is known regarding the efficacy of oral morphine for dyspnea among patients with cancer, including its response rate and predictive factors of effectiveness. Therefore, the aim of this study was to clarify the effectiveness of oral morphine on dyspnea in patients with cancer and elucidate the predictive factors of its effectiveness. Subjects, Materials, and Methods: In this multicenter prospective observational study, we investigated the change in dyspnea intensity in patients with cancer before and after the administration of oral morphine by using a visual analog scale (VAS). We also administered a self-assessment questionnaire to determine whether the patients believed oral morphine was effective. Results: Eighty patients were enrolled in the study, and 71 of these patients were eligible. The least square mean of the VAS scores for dyspnea intensity was 53.5 at baseline, which decreased significantly to 44.7, 40.8, and 35.0 at 30, 60, and 120 minutes after morphine administration, respectively. Fifty-four patients (76.1%) reported that oral morphine was effective on the self-assessment questionnaire. Among the background factors, a high score for “sense of discomfort” on the Cancer Dyspnea Scale (CDS) and a smoking history of fewer pack-years were associated with greater effectiveness. Conclusion: Oral morphine was effective and feasible for treating cancer-related dyspnea. A higher score for “sense of discomfort” on the CDS and a smaller cumulative amount of smoking may be predictive factors of the effectiveness of oral morphine. Implications for Practice: This study demonstrated that oral morphine was effective in alleviating cancer-related dyspnea due to multiple factors including primary lung lesions, airway narrowing, and pleural effusion. Approximately 76% of patients reported that oral morphine was effective. A higher score for “sense of discomfort” on the Cancer Dyspnea Scale and a lower cumulative amount of smoking may be predictive factors for the effectiveness of oral morphine. Interestingly, respiratory rates in patients who reported the morphine to be effective decreased significantly after oral morphine administration, unlike the respiratory rates in “morphine-ineffective” patients.
  • 前田 真吾, 榊原 洋介, 山蔦 久美子, 岡村 拓哉, 峯澤 智之, 後藤 康洋, 林 正道, 磯谷 澄都, 近藤 征史, 今泉 和良, 栃井 大輔, 栃井 祥子, 須田 隆, 星川 康
    肺癌 58(7) 1009-1010 2018年12月  
  • Sumito Isogai, Naoki Yamamoto, Noriko Hiramatsu, Yasuhiro Goto, Masamichi Hayashi, Masashi Kondo, Kazuyoshi Imaizumi
    Cellular reprogramming 20(6) 347-355 2018年12月  
    Since induced pluripotent stem (iPS) cells have been established, in recent years, clinical transplantation of cells differentiated from iPS cells derived from human skin fibroblasts is been in progress. On the contrary, monocytes have complete genome information without damage and gene recombination, they are contained in the peripheral blood by ∼3%-8% and differentiate into dendritic cells that are the type of control tower for immune cells. However, generation of monocyte-derived iPS cells has only been successful when special persistent Sendai virus vectors have been used. Therefore, in this study, as a preculture method for monocytes, a culture method for maintaining activity without using any cytokine was established, and using a commercially available vector without genetic toxicity without damaging the chromosome of the cell, iPS cells derived from monocytes were successfully produced. This cell has the ability to differentiate into three germ layers, and when compared with commercially available iPS cells, there was no significant difference between self-renewal and gene expression in the three germ layers. In future, we will compare the differentiation induction of monocyte-derived iPS cells with dendritic cells and investigate the production of dendritic cells that can cope with various antigens.

共同研究・競争的資金等の研究課題

 3

その他

 1